Zolgensma Stands Out In Strong Q4 For Novartis
Big Sales Rises For Cosentyx And Entresto
Executive Summary
CEO Vas Narasimhan is confident the Swiss major's gene therapy for spinal muscular atrophy will outperform present and future rivals – Biogen's Spinraza and Roche's risdiplam, respectively – as "we have a better profile simply because we are a one-time therapy."
You may also be interested in...
Novartis, D&A Pharma Prepare For High-Stake EMA Meetings
Oral explanation meetings are due to take place this week for drug sponsors who have a final chance to address questions and concerns the European Medicines Agency has about their marketing applications.
For Novartis' Generic Advair, Another 18 Months Was Too Far Into The Unknown
Company did not kill its development program because of US FDA feedback, but the experience seems to be another lesson in the difficulty in gaining approval for complex generics.
US Biosimilars Take A Bite Out Of Roche's Herceptin, But Tecentriq Surges
Roche's Q4 and full year results are slightly below expectations, but analysts still see it as one of sector's strong performers in 2020.